Vancomycin resistance in Staphylococci

Clinical Microbiology Reviews

Volumn 15, Issue 3, 2002, Pages 430-438

  Srinivasan, Arjun ^a   Dick, James D ^a   Perl, Trish M ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; DOXYCYCLINE; GENTAMICIN; LINEZOLID; NAFCILLIN; RIFAMPICIN; TOBRAMYCIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; COAGULASE NEGATIVE STAPHYLOCOCCUS; INFECTION CONTROL; LABORATORY DIAGNOSIS; NONHUMAN; REVIEW; RISK FACTOR; STAPHYLOCOCCUS;

ANTI-BACTERIAL AGENTS; HUMANS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

POSIBACTERIA; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

EID: 0036310636     PISSN: 08938512     EISSN: None     Source Type: Journal    
DOI: 10.1128/CMR.15.3.430-438.2002     Document Type: Review

References (83)

1. Antimicrobial susceptibility and selection of resistance among Staphylococcus epidermidis isolates recovered from patients with infections of indwelling foreign devices
2. RP 59500, a new streptogramin highly active against recent isolates of North American staphylococci
3. Selection of vancomycin- and teicoplanin-resistant Staphylococcus haemolyticus during teicoplanin treatment of S. epidermidis infection
4. Evaluation of the antimicrobial susceptibilities of coagulase-negative staphylococci by E-test
5. Glycopeptide resistance in coagulase-negative staphylococci
6. Peptidoglycan synthesis and structure in Staphylococcus haemolyticus expressing increasing levels of resistance to glycopeptide antibiotics
7. Outbreak of multidrug-resistant Enterococcus faecium with transferable vanB class vancomycin resistance
8. Spread of methicillin-resistant Staphylococcus aureus in a hospital after exposure to a health care worker with chronic sinusitis
9. Environmental contamination due to methicillin-resistant Staphylococcus aureus: Possible infection control implications
10. Molecular basis for vancomycin resistance in Enterococcus faecium BM4147: Biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance proteins VanH and VanA
11. Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC)
12. Interim guidelines for prevention and control of staphylococcal infection associated with reduced susceptibility to vancomycin
13. Reduced susceptibility of Staphylococcus aureus to vancomycin - Japan, 1996
14. Laboratory capacity to detect antimicrobial resistance, 1998
15. Staphylococcus aureus with reduced susceptibility to vancomycin - Illinois, 1999
16. Combinations of vancomycin and beta-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin
17. Characterization of Staphylococcus aureus isolates with decreased susceptibility to vancomycin and teicoplanin: Isolation and purification of a constitutively produced protein associated with decreased susceptibility
18. Antimicrobial susceptibility of coagulase-negative staphylococci and characterization of isolates with reduced susceptibility to glycopeptides
19. Resistance of staphylococci in The Netherlands: Surveillance by an electronic network during 1989-1995
20. Staphylococcus epidermidis with intermediate resistance to vancomycin: Elusive phenotype or laboratory artifact?
21. The epidemiology of intravenous vancomycin usage in a university hospital. A 10-year study
22. Trends in grampositive bloodstream organism resistance: A seven-year audit of five glycopeptides and other drugs at a large university hospital
23. European Glycopeptide Susceptibility Survey of gram-positive bacteria for 1995
24. Vancomycin-intermediate and -resistant Staphylococcus aureus: What the infectious disease specialist needs to know
25. Antimicrobial resistance in nosocomial isolates of Staphylococcus haemolyticus
26. The emergence of decreased susceptibility to vancomycin in Staphylococcus epidermidis
27. Some laboratory and clinical experiences with a new antibiotic, vancomycin
28. Percentages and distributions of teicoplanin- and vancomycin-resistant strains among coagulase-negative staphylococci
29. Clinical relevance of a European collaborative study on comparative susceptibility of gram-positive clinical isolates to teicoplanin and vancomycin
30. Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50
31. High incidence of antibiotic resistance among bacteria in 4 intensive care units at a university hospital in Sweden
32. Susceptibility of Gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid
33. In vitro selection of resistance to vancomycin in bloodstream isolates of Staphylococcus haemolyticus and Staphylococcus epidermidis
34. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin
35. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility
36. Glycopeptide-intermediate Staphylococcus aureus: Evaluation of a novel screening method and results of a survey of selected U.S. hospitals
37. In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species
38. Nosocomial bacteremia due to vancomycin-resistant Staphylococcus epidermidis in four patients with cancer, neutropenia, and previous treatment with vancomycin
39. Trends in antibiotic resistance of staphylococci over an eight-year period: Differences in the emergence of resistance between coagulase positive and coagulase-negative staphylococci
40. Quinupristin-dalfopristin resistance among gram-positive bacteria in Taiwan
41. Persistence of a multiresistant clone of Staphylococcus epidermidis in a neonatal intensive-care unit for a four-year period
42. The specter of glycopeptide resistance: Current trends and future considerations
43. Increased production of penicillin-binding protein 2, increased detection of other penicillin-binding proteins, and decreased coagulase activity associated with glycopeptide resistance in Staphylococcus aureus
44. Methicillin-resistant Staphylococcus aureus: A consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management
45. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus
46. Antistaphylococcal (MSSA, MRSA, MSSE, MRSE) antibiotics
47. The threat of vancomycin resistance
48. Investigation of suspected nosocomial clusters of Staphylococcus haemolyticus infections
49. An outbreak of Staphylococcus aureus strains with reduced susceptibility to glycopeptides in a French general hospital
50. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital
51. Clinically significant coagulase-negative staphylococci: Identification and resistance patterns
52. Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia
53. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium
54. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains
55. Patterns of multidrug resistance among methicillin-resistant hospital isolates of coagulase-positive and coagulase-negative staphylococci collected in the international multicenter study RESIST in 1997 and 1998
56. Peritonitis due to vancomycin-resistant Staphylococcus epidermidis
57. Selection for vancomycin resistance in clinical isolates of Staphylococcus haemolyticus
58. Emergence of vancomycin resistance in coagulase-negative staphylococci
59. Vancomycin resistance plasmid in Enterococcus faecalis that encodes sensitivity to a sex pheromone also produced by Staphylococcus aureus
60. Synergy of vancomycin plus cefazolin or cephalothin against methicillin-resistance Staphylococcus epidermidis
61. Inactivated pbp4 in highly glycopeptide-resistant laboratory mutants of Staphylococcus aureus
62. Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus
63. Gradual alterations in cell wall structure and metabolism in vancomycin-resistant mutants of Staphylococcus aureus
64. Decreased susceptibilities to teicoplanin and vancomycin among coagulase-negative methicillin-resistant clinical isolates of staphylococci
65. Inactivation of the methicillin resistance gene mecA in vancomycin-resistant Staphylococcus aureus
66. Emergence of vancomycin resistance in Staphylococcus aureus
67. Implications of vancomycin-resistant Staphylococcus aureus
68. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus
69. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides
70. Ability of laboratories to detect emerging antimicrobial resistance: Proficiency testing and quality control results from the World Health Organization's external quality assurance system for antimicrobial susceptibility testing
71. Prevalence of antibiotic resistance among clinical isolates of methicillin-resistant staphylococci
72. Linezolid resistance in a clinical isolate of Staphylococcus aureus
73. Clinical and microbiologic aspects of serious infections caused by Staphylococcus epidermidis
74. A multicentre study: Staphylococcus and Enterococcus susceptibility to antibiotics
75. Vancomycin intermediate-resistant Staphylococcus aureus
76. Antimicrobial resistance of coagulase-negative staphylococci from a Kuwait hospital
77. Vancomycin resistance in Staphylococcus haemolyticus causing colonization and bloodstream infection
78. Nationwide German multicenter study on prevalence of antibiotic resistance in staphylococcal bloodstream isolates and comparative in vitro activities of quinupristin-dalfopristin
79. Mode of action and in-vitro activity of vancomycin
80. Vancomycin-resistant Staphylococcus aureus: Infection control considerations
81. Bacteremia caused by staphylococci with inducible vancomycin heteroresistance
82. Vancomycin, a new antibiotic II. In vitro-antibacterial studies